Tarsus Pharmaceuticals (TARS) Stock Chart & Stock Price History $50.65 -0.36 (-0.71%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$51.25 +0.60 (+1.19%) As of 08:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Tarsus Pharmaceuticals Stock Price Performance 5 Day Performance+1.36%1 Month Performance+13.87%3 Month Performance-7.91%6 Month Performance+55.80%Year-To-Date Performance-8.52%1 Year Performance+39.34% Receive TARS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Stock Chart for Friday, March, 28, 2025 TARS Chart by TradingViewRemove Ads Tarsus Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization03/27/2025$51.01$50.65-0.71%$51.33$49.531.65 million shs$1.94 billion03/26/2025$51.33$51.01-0.62%$51.71$49.53291,655 shs$1.96 billion03/25/2025$52.36$51.33-1.97%$52.27$50.84692,967 shs$1.97 billion03/24/2025$49.97$52.36+4.78%$52.63$48.401.10 million shs$2.01 billion03/21/2025$49.91$49.97+0.12%$51.14$48.27595,518 shs$1.92 billion03/20/2025$49.55$49.91+0.73%$50.98$49.31618,361 shs$1.92 billion03/19/2025$46.17$49.55+7.32%$49.73$45.54703,213 shs$1.90 billion03/18/2025$47.49$46.17-2.78%$47.06$45.39869,721 shs$1.77 billion03/17/2025$48.09$47.49-1.25%$48.34$47.00413,634 shs$1.82 billion03/14/2025$46.47$48.09+3.49%$48.23$45.60487,715 shs$1.85 billion Get the Latest News and Ratings for TARS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 03/13/2025$47.10$46.47-1.34%$48.96$45.221.09 million shs$1.78 billion03/12/2025$47.15$47.10-0.11%$49.90$46.92683,309 shs$1.81 billion03/11/2025$44.59$47.15+5.74%$47.20$43.93554,365 shs$1.81 billion03/10/2025$46.47$44.59-4.05%$45.87$43.74485,106 shs$1.78 billion03/07/2025$43.57$46.47+6.66%$46.77$43.32625,250 shs$1.78 billion03/06/2025$44.54$43.57-2.18%$44.39$43.15299,311 shs$1.67 billion03/05/2025$44.50$44.54+0.09%$44.83$43.29468,364 shs$1.71 billion03/04/2025$42.72$44.50+4.17%$45.68$41.30564,310 shs$1.71 billion03/03/2025$44.48$42.72-3.96%$44.75$42.51779,981 shs$1.64 billion02/28/2025$43.55$44.48+2.14%$44.81$43.03845,617 shs$1.70 billion02/27/2025$42.56$43.55+2.33%$44.42$41.11827,048 shs$1.66 billion Related Companies Roivant Sciences Stock Price Chart Sarepta Therapeutics Stock Price Chart Revolution Medicines Stock Price Chart BridgeBio Pharma Stock Price Chart Lantheus Stock Price Chart TG Therapeutics Stock Price Chart Legend Biotech Stock Price Chart Axsome Therapeutics Stock Price Chart Telix Pharmaceuticals Limited American Depositary Shares Stock Price Chart Blueprint Medicines Stock Price Chart Receive TARS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:TARS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
